New cancer drugs: little extra benefit, higher price

New anticancer drugs reaching the European market in 1995-2000 offer few or no substantial advantages over existing preparations yet cost several times as much. Garattini and Bertele' (p 269) outline the features of the 12 new anticancer drugs approved for marketing and say that the general population of cancer patients will gain no benefit from them. It is hoped, however, that some new anticancer drugs, such as anti-angiogenic agents and resistant revertants, will soon undergo adequate clinical testing and show benefits over current treatments.

(Credit: RAY TANG/REX)

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.